At a symposium sponsored by Schering-Oncology/Biotech, 16 researchers involved in studies of the investigational antiestrogen agent toremifene (Fareston) discussed its potential role in the treatment of patients with advanced breast cancer and as adjuvant therapy, as well as other breast cancer issues. Previous articles in this series appeared in January 1997 , February 1997 , and March 1997
BERN, Switzerland--A study of 1,619 breast cancer patients has identified a population subset with a very low incidence of lymph node metastases in whom axillary lymph node dissection might be omitted, Andreas Barth, MD, told Oncology News International.
MIAMI BEACH, Fla--Radiation therapy may not be necessary after the removal of ductal carcinoma in situ (DCIS), Gordon F. Schwartz, MD, said at the 14th International Breast Cancer Conference. In his experience, only 3% of DCIS patients who received breast-conserving surgery alone later experienced invasive breast cancer.
PARIS--The treatment of breast cancer in pregnant women remains controversial, not least because pregnant and lactating women are traditionally excluded from clinical trials. Now a prospective long-term study from M.D. Anderson Cancer Center suggests that multimo-dality treatment does not pose any untoward threat to either mother or child.
HOUSTON--A new tumor-selective agent may permit delivery of higher levels of 5-fluorouracil (5-FU) with lower toxicity, said Richard Pazdur, MD, of M.D. Anderson Cancer Center. A phase III trial of capecitabine is ongoing in colorectal cancer, and it is also under study for the treatment of breast cancer.
FORT LAUDERDALE, Fla--There still is insufficient evidence about the use of high-dose chemotherapy plus bone marrow or peripheral stem cells to support its inclusion as a path on the updated National Comprehensive Cancer Network (NCCN) practice guidelines on breast cancer, said panel chair Robert W. Carlson, MD, at the NCCN's second annual conference
PARIS--A newly identified segment of an RNA retrovirus may be implicated in as many as one third of breast tumors, James Holland, MD, of Mount Sinai Medical Center, NY, said at the Seventh International Congress on Anti-Cancer Treatment (ICACT). The segment of the putative virus, thought to be a human mammary tumor virus (HMTV), was discovered in the laboratory of Dr. Beatriz Pogo at Mount Sinai.
FORT LAUDERDALE, Fla--In view of the absence of data from large randomized studies of high-dose chemotherapy in breast cancer, the NCCN breast cancer guidelines' relegation of such therapy to a footnote is appropriate, M. John Kennedy, MD, said in his review of the important issues on this question.
The recognition of paclitaxel's (Taxol's) activity and non-cross-resistance with doxorubicin (Adriamycin) in the treatment of metastatic breast cancer has motivated study of the agent in the adjuvant setting. However, the ideal
Based on preclinical data, we designed a phase I/II clinical trial to determine the efficacy and toxicity of doxorubicin followed by paclitaxel in the treatment of advanced breast cancer (either untreated or relapsed after
When administered as a single agent in pretreated patients with advanced breast cancer, paclitaxel (Taxol) exhibits remarkable antitumor activity. This trial was undertaken to compare paclitaxel with standard
An expert panel of 10 international cancer researchers and practicing oncologists met in Boston to discuss the past, present, and future uses of antiestrogens in the treatment of breast cancer. The first five articles in this series, based
Paclitaxel (Taxol) has aroused considerable interest for its high single-agent activity in breast cancer and novel mechanism of action. Epirubicin (Farmorubicin), the 4'epimer of doxorubicin (Adriamycin), also has high activity in
This phase II trial was conducted to evaluate the percentage of objective responses and the toxicity profile of combination doxorubicin (Adriamycin) and paclitaxel (Taxol) with granulocyte colony-stimulating factor as first-line
WASHINGTON--The steering committee of the National Action Plan on Breast Cancer (NAPBC) finds itself confronting its future--whether it should have one. Should the group set a time to end the innovative program, or should it continue?
SEATTLE--"Is it possible that at some point in human evolution, there was some selective advantage of BRCA1 and BRCA2?" Mary-Claire King, PhD, asked during her presentation at the annual meeting of the American Association for the Advancement of Science (AAAS).
Response to liarozole fumarate has been observed in patients with receptor-positive metastatic breast cancer, as well as those with receptor-unknown disease, confirming the biologic efficacy of this agent. The first clinical study of the role of liarozole in
PALM SPRINGS, Calif--Data from preclinical studies of the antiestro-gen agent toremifene (Fareston), and their correlation with data from clinical studies, may provide information useful in designing trials comparing toremifene with tamoxifen (Nolvadex) as adjuvant breast cancer therapy, Michael DeGregorio, PharmD, said at the symposium.
The controversies regarding the association between hormonal replacement therapy (HRT) and cancers, the questions about HRT use in women with a high risk of breast cancer, and the increasing number of women with breast cancer and menopausal symptoms make HRT a significant cancer issue.
Overexpression by the HER2 gene plays a significant role in breast cancer pathogenesis, and the phenomenon is commonly regarded as a predictor of a poor prognosis. HER2 overexpression has been linked to sensitivity and/or resistance to hormone therapy and chemotherapeutic regimens, including CMF (cyclophosphamide, methotrexate, and fluoro-uracil) and anthracyclines. Studies of patients with advanced disease demonstrate that, despite the association of HER2 overexpression with poor prognosis, the odds of HER2-positive patients responding clinically to taxanes were greater than three times those of HER2-negative patients. Further studies in preclinical models used combination therapy for breast cancer cells that overexpress HER2, and the use of agents that interfere with HER2 function plus paclitaxel (Taxol) resulted in significant antitumor effects. [ONCOLOGY 11(Suppl):43-48, 1997]
Clinical trials to develop paclitaxel (Taxol)-containing combinations started in 1992 with several approaches to combine doxorubicin and paclitaxel. Schedule-dependent toxicity limited doses in the initial trials, although antitumor activity was high. More recently, a well-tolerated, highly effective doxorubicin/paclitaxel regimen was developed with the use of bolus anthracycline administration and a 3-hour infusion of paclitaxel. Combinations of paclitaxel with cisplatin have provided mixed results. Paclitaxel combined with fluorouracil (5-FU) and folinic acid proved effective in patients with extensive prior chemotherapy; the addition of mitoxantrone (Novantrone) to this combination was feasible, well tolerated, and possibly enhanced the efficacy of paclitaxel and 5-FU. Combinations of paclitaxel with cyclophosphamide (Cytoxan, Neosar), vinorelbine (Navelbine), edatrexate, and radiation continue in clinical development. [ONCOLOGY 11(Suppl):29-37, 1997]
The following position statement was made by the American Association for Cancer Research in response to the press release on mammography screening for women 40 to 49 years old issued by the National Institutes of Health
The proven safety profile and antitumor activity of paclitaxel (Taxol) in the treatment of metastatic breast cancer led investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) to further examine the agent's potential in the treatment of advanced breast cancer. Efficacy and tolerability studies of paclitaxel as single-agent therapy were undertaken, along with parallel investigations of quality-of-life parameters. The studies examined the effects of 96-hour infusion schedules of paclitaxel and are currently assessing the feasibility of a weekly 1-hour infusion schedule. Researchers at MSKCC also compared the results of a variety of two- and three-drug paclitaxel-containing regimens to determine possible synergism and better define safety profiles. They examined the combination of paclitaxel and edatrexate, as well as a promising combination of paclitaxel and a monoclonal antibody directed at growth factor receptors. The latter ongoing trial will include both laboratory studies that examine possible cellular mechanisms for the combination's observed synergy and a clinical trial that combines paclitaxel with a monoclonal antibody directed against the epidermal growth factor. In conclusion, the investigators discuss the optimal integration of paclitaxel into doxorubicin/cyclophosphamide (Cytoxan, Neosar)-based adjuvant therapy for node-positive stage II-III resectable breast cancer. [ONCOLOGY 11(Suppl):20-28, 1997]
The extensively studied agent docetaxel (Taxotere) has shown marked clinical activity in the treatment of anthracycline-resistant breast cancer. Phase I trials indicate that toxicities, such as mucositis and neutropenia, limit the administration of docetaxel to shorter perfusion schedules. Pharmacokinetic studies have shown that docetaxel's clearance by hepatic metabolism is correlated with a marked increase in risk of toxicity in patients with impaired liver function. Nevertheless, studies of docetaxel as front-line therapy for breast cancer were initiated because of its good activity against tumors in early studies and its close relationship to paclitaxel (Taxol), an agent with proven efficacy. Phase II studies have demonstrated excellent activity for docetaxel as a single agent, with an overall response rate of 61% in trials of a 100-mg/m² dose. A phase III study is currently comparing docetaxel with paclitaxel as single-agent therapy. Docetaxel is expected to provide a better response rate but a higher incidence of neutropenia. The agent shows promise in adjuvant therapy, with very high response rates in anthracycline-resistant patients. Preliminary results of tests using docetaxel in combination with doxorubicin show high objective response rates but low complete response rates; early results suggest that this combination may have some advantages over paclitaxel/doxorubicin. [ONCOLOGY 11(Suppl):38-42, 1997]
Despite the results of the National Surgical Adjuvant Breast and Bowel Project B-17, there continues to be debate regarding the most appropriate treatment for patients with ductal carcinoma in situ (DCIS) of the breast. Numerous clinical, pathologic, and laboratory factors can aid clinicians and patients wrestling with the difficult
